Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Ashwaq Alsahafi"'
Autor:
Waleed Al-Hamoudi, Khalid Alswat, Ayman A. Abdo, Waleed A. Mousa, Abduljaleel M. Alalwan, Yaser Dahlan, Abdulrahman Aljumah, Adnan AlZanbagi, Abdallah AlMousa, Hamdan S. Alghamdi, Abdelrahman Awny, Ashwaq Alsahafi, Mohammed AlJawad, Mohamed A. Babatin, Abdullah M. Assiri, Ibrahim Altraif, Haziz Albiladi, Faisal M. Sanai, Nawaf H Almutairi, Ali Albenmousa, Mohammed S. AlSaleemi, Abdullah S. Alghamdi, Hammad S. Alothmani
Publikováno v:
Journal of Infection. 76:536-542
Summary Limited clinical trial data has shown high efficacy of co-formulated ledipasvir/sofosbuvir (LDV/SOF) in the treatment of hepatitis C virus (HCV) genotype (GT)-4 infected cirrhotic patients. We assessed real-world safety and efficacy of LDV/SO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4078e4deb0bc854dbc449513185df82
https://doi.org/10.1016/j.jinf.2018.04.001
https://doi.org/10.1016/j.jinf.2018.04.001
Autor:
Haziz Albiladi, Abdullah S. Alghamdi, Mohammed Almugharbal, Khalid I. Bzeizi, Mohammed A. Babatin, Abdulla Alaseeri, Hammad S. Alothmani, Faisal M. Sanai, Ali Albenmousa, Ashwaq Alsahafi, Mahdi Aljarodi
Publikováno v:
Journal of clinical gastroenterology. 52(5)
INTRODUCTION The combination of sofosbuvir (SOF) with simeprevir (SMV) or daclatasvir (DCV) is very effective in treating hepatitis C virus (HCV) infection, particularly genotype (GT) 1. However, the data on GT4 are very limited. We aimed to determin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a3c7f870522ba83307fc0f317123b67
https://pubmed.ncbi.nlm.nih.gov/28767462
https://pubmed.ncbi.nlm.nih.gov/28767462